• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

索林碳酸氢盐假体的单机构19年经验

Nineteen Years of Single Institute Experiences with Sorin Bicarbon Prosthesis.

作者信息

Van Hung Dung

机构信息

Ho Chi Minh Heart Institute, Ho Chi Minh, Viet Nam.

出版信息

Ann Thorac Cardiovasc Surg. 2019 Aug 20;25(4):192-199. doi: 10.5761/atcs.oa.18-00223. Epub 2019 Mar 12.

DOI:10.5761/atcs.oa.18-00223
PMID:30867384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6698711/
Abstract

PURPOSE

We want to share our experience of Sorin Bicarbon prosthesis (SBP) after 19 years follow-up.

METHODS

Retrospective study of 1377 patients who had replaced with SBP from May 1998 to December 2008 at Ho Chi Minh Heart Institute, Viet Nam.

RESULTS

Male patients was 42%, mean age was 40.2 ± 11.8 years. Atrial fibrillation was 43.5%. The main cause of valvular disease was rheumatic fever (89.8%). Isolated mitral valve replacement (MVR): 54% (744), isolated aortic valve replacement (AVR): 18% (247), double valve replacement (DVR): 26% (359), and 27 AVR plus mitral repair. 30-day mortality for all was 1.5%. Mean time of follow-up was 153 ± 53.1 months with total follow-up time was 17563 patients-years. 2.5% lost of follow-up. Late death was 77 cases. Redo for all causes was 59 cases. 19 years survival was 88.8 ± 1.8%. 19 years freedom of redo was 76.4 ± 4.7%. Linearized rate of all valve thrombosis, embolism, severe bleeding, endocarditis, and pannus were 0.31%, 0.28%, 0.267%, 0.068%, and 0.165% patient-years, respectively.

CONCLUSIONS

SBP had shown very good results in long term and still have a reliable mechanical valve.

摘要

目的

我们希望分享索林双叶机械瓣(SBP)19年随访的经验。

方法

对1998年5月至2008年12月在越南胡志明心脏研究所接受SBP置换的1377例患者进行回顾性研究。

结果

男性患者占42%,平均年龄为40.2±11.8岁。房颤发生率为43.5%。瓣膜疾病的主要病因是风湿热(89.8%)。单纯二尖瓣置换(MVR):54%(744例),单纯主动脉瓣置换(AVR):18%(247例),双瓣置换(DVR):26%(359例),以及27例AVR加二尖瓣修复。所有患者的30天死亡率为1.5%。平均随访时间为153±53.1个月,总随访时间为17563患者年。2.5%的患者失访。晚期死亡77例。因各种原因再次手术59例。19年生存率为88.8±1.8%。19年无再次手术率为76.4±4.7%。所有瓣膜血栓形成、栓塞、严重出血、心内膜炎和血管翳的线性化发生率分别为0.31%、0.28%、0.267%、0.068%和0.165%患者年。

结论

SBP长期显示出非常好的效果,仍然是一种可靠的机械瓣膜。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0703/6698711/0e9d30208780/atcs-25-192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0703/6698711/d99669d77545/atcs-25-192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0703/6698711/0e9d30208780/atcs-25-192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0703/6698711/d99669d77545/atcs-25-192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0703/6698711/0e9d30208780/atcs-25-192-g002.jpg

相似文献

1
Nineteen Years of Single Institute Experiences with Sorin Bicarbon Prosthesis.索林碳酸氢盐假体的单机构19年经验
Ann Thorac Cardiovasc Surg. 2019 Aug 20;25(4):192-199. doi: 10.5761/atcs.oa.18-00223. Epub 2019 Mar 12.
2
Single center experience with the Sorin Bicarbon prosthesis: a 17-year clinical follow-up.索林碳酸氢盐假体的单中心经验:17年临床随访
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2039-44. doi: 10.1016/j.jtcvs.2013.11.015. Epub 2013 Dec 9.
3
Sorin Bicarbon bileaflet valve: a 9.8-year experience. Clinical performance of the prosthesis after heart valve replacement in 587 patients.索林双叶瓣:9.8年的经验。587例患者心脏瓣膜置换术后人工瓣膜的临床性能。
Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):252-9. doi: 10.1510/icvts.2008.183590. Epub 2008 Nov 20.
4
Mechanical Heart Valve Replacement in a Low-Middle Income Region in the Modern Era: Midterm Results from a Sub-Saharan Center.现代中低收入地区的机械心脏瓣膜置换术:撒哈拉以南某中心的中期结果
Thorac Cardiovasc Surg. 2020 Mar;68(2):99-106. doi: 10.1055/s-0038-1666873. Epub 2018 Jul 18.
5
Evaluation of valve-related complications in patients with Sorin Bicarbon prosthesis: a seven-year experience.索林碳酸氢盐人工瓣膜患者瓣膜相关并发症的评估:七年经验
J Heart Valve Dis. 2001 Nov;10(6):795-801.
6
Midterm experience with the Sorin Bicarbon heart valve prosthesis for rheumatic disease.索林碳酸氢盐心脏瓣膜假体治疗风湿性疾病的中期经验。
J Cardiovasc Surg (Torino). 2003 Oct;44(5):597-603.
7
Mitral and mitro-aortic valve replacement with Sorin Bicarbon valves compared with St. Jude Medical valves.使用索林碳酸氢盐瓣膜与圣犹达医疗瓣膜进行二尖瓣和二尖瓣-主动脉瓣置换术的比较。
Cardiovasc Surg. 2001 Jun;9(3):272-80. doi: 10.1016/s0967-2109(00)00136-8.
8
Midterm evaluation of the Sorin Bicarbon heart valve prosthesis: single-center experience.索林双叶心脏瓣膜假体的中期评估:单中心经验
Ann Thorac Surg. 2004 Feb;77(2):527-31. doi: 10.1016/S0003-4975(03)01347-X.
9
Single-institution, 22-year follow-up of 786 CarboMedics mechanical valves used for both primary surgery and reoperation.单中心 22 年随访 786 例初次手术和再次手术中使用的 CarboMedics 机械瓣膜。
J Thorac Cardiovasc Surg. 2014 May;147(5):1493-8. doi: 10.1016/j.jtcvs.2013.05.017. Epub 2013 Jul 13.
10
Redo quadruple-valve repair after Ross procedure: a viable option?罗斯手术(Ross procedure)后再次进行四瓣膜修复:一个可行的选择?
Asian Cardiovasc Thorac Ann. 2018 Feb;26(2):151-153. doi: 10.1177/0218492317733110. Epub 2017 Sep 14.

引用本文的文献

1
Regression of Left Ventricular Hypertrophy After Aortic Valve Replacement with Sorin Freedom Solo and St. Jude Regent Valves: a Comparative Study.使用索林Freedom Solo瓣膜和圣犹达Regent瓣膜进行主动脉瓣置换术后左心室肥厚的消退:一项比较研究。
Acta Inform Med. 2025;33(2):123-128. doi: 10.5455/aim.2025.33.123-128.
2
Making a difference: 5 years of Cardiac Surgery Intersociety Alliance (CSIA).改变现状:心脏外科学会联盟(CSIA)五载。
Asian Cardiovasc Thorac Ann. 2024 Jun;32(5):271-284. doi: 10.1177/02184923241259191. Epub 2024 Jun 13.
3
Making a difference: 5 years of Cardiac Surgery Intersociety Alliance (CSIA).

本文引用的文献

1
Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center.在单一中心使用碳酸氢盐心脏瓣膜假体的十五年经验。
J Cardiothorac Surg. 2015 Jun 28;10:89. doi: 10.1186/s13019-015-0294-x.
2
Single center experience with the Sorin Bicarbon prosthesis: a 17-year clinical follow-up.索林碳酸氢盐假体的单中心经验:17年临床随访
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2039-44. doi: 10.1016/j.jtcvs.2013.11.015. Epub 2013 Dec 9.
3
Twenty-year experience with the CarboMedics mechanical valve prosthesis.二十年来对 CarboMedics 机械瓣膜假体的应用经验。
成就斐然:心脏外科学会联盟(CSIA)五载历程。
Eur J Cardiothorac Surg. 2024 Jun 3;65(6). doi: 10.1093/ejcts/ezae048.
4
Mortality Rates of Surgical Techniques for Correcting Atrioventricular Disjunction.房室连接纠正术的手术技术死亡率。
Braz J Cardiovasc Surg. 2020 Dec 1;35(6):994-998. doi: 10.21470/1678-9741-2020-0041.
Ann Thorac Surg. 2014 Mar;97(3):816-23. doi: 10.1016/j.athoracsur.2013.09.098. Epub 2013 Nov 23.
4
Acute obstruction by Pannus in patients with aortic medtronic-hall valves: 30 years of experience.主动脉 Medtronic-Hall 瓣患者的血管翳急性梗阻:30 年经验。
Ann Thorac Surg. 2013 Dec;96(6):2123-8. doi: 10.1016/j.athoracsur.2013.07.019. Epub 2013 Sep 23.
5
Patient-prosthesis mismatch in patients with aortic valve replacement.主动脉瓣置换患者的人工瓣膜-患者不匹配
Gen Thorac Cardiovasc Surg. 2013 May;61(5):274-9. doi: 10.1007/s11748-013-0216-6. Epub 2013 Feb 13.
6
The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years.假体-患者不匹配对主动脉瓣置换术后长期生存的影响:34 项观察性研究的系统评价和荟萃分析,共纳入 27186 例患者和 133141 患者年。
Eur Heart J. 2012 Jun;33(12):1518-29. doi: 10.1093/eurheartj/ehs003. Epub 2012 Mar 8.
7
The Sorin Bicarbon over 15 years clinical outcomes: multicentre experience in 1704 patients.Sorin 碳酸氢盐超过 15 年的临床结果:1704 例患者的多中心经验。
Eur J Cardiothorac Surg. 2010 Dec;38(6):759-66. doi: 10.1016/j.ejcts.2010.03.060. Epub 2010 May 14.
8
Fifteen years of experience with ATS mechanical heart valve prostheses.ATS 机械心脏瓣膜假体 15 年的经验。
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1494-500. doi: 10.1016/j.jtcvs.2009.07.039. Epub 2009 Sep 10.
9
Sorin Bicarbon bileaflet valve: a 9.8-year experience. Clinical performance of the prosthesis after heart valve replacement in 587 patients.索林双叶瓣:9.8年的经验。587例患者心脏瓣膜置换术后人工瓣膜的临床性能。
Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):252-9. doi: 10.1510/icvts.2008.183590. Epub 2008 Nov 20.
10
Guidelines for reporting mortality and morbidity after cardiac valve interventions.心脏瓣膜干预后死亡率和发病率报告指南。
J Thorac Cardiovasc Surg. 2008 Apr;135(4):732-8. doi: 10.1016/j.jtcvs.2007.12.002.